Introduction: Isolated limb perfusion and infusion (ILP/ILI) are therapies for regional
INTRODUCTION
While melanoma accounts for approximately 5% of all skin cancers in the United States (US), it is responsible for about 90% of all skin cancer deaths [1] [2] [3] . According to the Surveillance, Epidemiology and End Results (SEER) program, the incidence of melanoma has been increasing for the last 30 years. In 2014, there were an estimated 76,100 new cases and 9710 melanoma-associated deaths in the US [4] .
The goals of treatment for melanoma are cure, local control, or palliation, and are mainly determined by the stage of disease. For localized lesions (Stages I and II, American Joint
Committee on Cancer, 7th edition) removal of the tumor by wide resection is potentially curative. If there is a loco-regional recurrence following initial surgery, additional surgical attempts can be considered [24] . At a certain point, patients may be considered unresectable based on the number of failed prior attempts for surgical cure or the technical unfeasibility of additional surgery. For patients with melanoma in-transit (Stage IIIB or IIIC), the goal of treatment is maintenance of local disease control and prevention of disease progression to distant metastases, including visceral metastases (Stage IV) [5] . For patients with advanced disease, cure after surgery alone is rare. The main treatment modality for Stage IV disease is systemic drug treatment to reduce tumor burden with the aim of prolonging survival and decreasing symptoms [6] . 
METHODS

Data Source
This was a retrospective, observational study using a large administrative claims database from the Truven Health Analytic MarketScan At least one claim of melanoma with an ICD-9-CM diagnosis code (principal or secondary) any time between the admission and discharge dates was required to ensure that the ILP/ILI procedure was for melanoma treatment.
Outcome Measures
The main outcome measures in this analysis were patterns of ILP/ILI use, length of hospital stay (LOS), and hospitalization costs of ILP/ILI. LOS was calculated based on the number of days between the admission and discharge dates from the hospital. Costs were computed as the combined health plan and patient paid amount, and were adjusted using the annual medical care component of the consumer price index to reflect inflation between 2002 and 2014 [19] . Comorbidity Index score (excluding cancers) [22, 23] .
This article does not contain any new studies with human or animal subjects performed by any of the authors.
RESULTS
Patient Characteristics
A total of 113 patients met the study criteria and were included in the analysis. Mean patient age was 61.4 years [standard deviation (SD) 13.8] and 38.9% of patients were male. The mean baseline Charlson Comorbidity Index score was 0.19% and 34.5% of patients were Medicare beneficiaries.
Overall, 87.6% of patients had primary melanoma of the lower limb, 11.5% of the upper limb, and 0.9% of both the upper and lower limbs; 60.2% had lymph node metastasis and 56.6% had skin metastasis within 1 year prior to the discharge date of the hospitalization.
A summary of the patient demographic characteristics is reported in Table 1 .
Patterns of ILP/ILI Use
Of the 113 patients identified, the majority Utilization Project (HCUP), the average hospital cost (physician cost not included in the report) for a surgical procedure was US$20,500 in 2013 [20] . Therefore, the costs of ILP/ILI procedures are higher than those of an Indirect costs associated with ILP/ILI were not examined due to lack of indirect cost information in the database. Considering that metastatic melanoma affects the working age population, indirect costs related to the recovery period at home, concomitant medication such as antibiotics or painkillers, and rehabilitation processes could be considerable and add to the overall costs.
Furthermore, the indirect cost associated with complication or morbidity due to ILP/ILI could also be substantial. Thus, the total costs of ILP/ ILI to society can be more expensive than said in the healthcare claims data.
CONCLUSIONS
The use of ILP and ILI was associated with long hospital stays and high costs. The results of this study may provide useful source data for the economic evaluation of treatment options for regional metastatic melanoma. 
